Identification of the Risk Factors of Bone Metastatic among Breast Cancer Women in Al-Bashir Hospital

Shaimaa  Shamoun; Ahmed A.  Al Ibraheemi

doi:10.4236/abcr.2018.72008

Shaimaa Shamoun¹, Ahmed A. Al Ibraheemi²

Abstract: Background: Bone metastasis with advance cancer stage forms approximately 85% of all cases. Breast cancer patients frequently suffer from bone pain, functional impairment due to bone metastasis which impacts negatively on their quality of life. Subjects and Methods: A retrospective study of breast cancer patients who have bone metastasis at diagnosis or developing bone metastasis during 5 years from breast cancer diagnosis (2011-2016) and who received zometa 4 mg monthly in radiotherapy department was included and conducted in 2017. We reviewed 107 female with breast cancer diagnosed by bone scan and/or PET scan as cases of bone metastasis enrolled. Questionnaire was designed to document all variables besides, demographic data which contain (age, histopathology reading invasive ductal carcinoma, invasive lobular carcinoma or others, ER status, PR status, Her2neu status and lymph node status & stage, Onset of metastasis, Menopausal Status & finally No. of metastasis site). Results: We noticed that the highest percentage of patients diagnosed as bone metastasis were 45 years and more, and 86% of them were invasive ductal carcinoma; regarding hormonal status we noticed that ER, PR status was positive in 90.7% and 82.2% of cases respectively, Her2neu receptors were amplified in 26.2% of them, positive lymph nodes were seen positive in 80.4% of cases and 31.8% of them were shown (N3) stage; we noticed that the only risk factor of bone metastasis is PR+ significantly associated with lesions multiplicity (0.049). There is no significant association between ER, PR, Her2neu, lymph nodes and menopausal status and onset of bone metastasis, also age, ER, Her2neu, lymph nodes and menopausal status are not associated significantly with No. of metastatic lesions. Conclusion: PR+ is significantly associated with lesions multiplicity (0.049), which is considered as a risk factor of bone metastasis in our study.

Keywords: Risk Factors, Bone Lesion, Breast Cancer, Metastatic, Zometa

Cite this paper: Shamoun, S. and Al Ibraheemi, A. (2018) Identification of the Risk Factors of Bone Metastatic among Breast Cancer Women in Al-Bashir Hospital. Advances in Breast Cancer Research, 7, 120-129. doi: 10.4236/abcr.2018.72008.

References

[1] Walkington, L. and Coleman, R.E. (2011) Advances in Management of Bone Disease in Breast Cancer. Bone, 48, 80-87.
https://doi.org/10.1016/j.bone.2010.05.037

[2] Grávalos, C., Rodríguez, C., Sabino, A., et al. (2016) SEOM Clinical Guideline for Bone Metastases from Solid Tumours. Clinical and Translational Oncology, 18, 1243-1253.
https://doi.org/10.1007/s12094-016-1590-1

[3] Arch, V. (2017) Breast Carcinoma Subtypes Show Different Patterns of Metastatic Behavior. Virchows Archiv, 470, 275-283.
https://doi.org/10.1007/s00428-017-2065-7

[4] Cerner Multum, Inc. (2017) Version: 15.02.
https://www.drugs.com/pro/zometa.html

[5] Tanaka, R., Yonemori, K., Hirakawa, A., et al. (2016) Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients with Bone Metastases Undergoing Treatment with Bone-Modifying Agents. Oncologist, 21, 508-513.
https://doi.org/10.1634/theoncologist.2015-0377

[6] Kohno, N., Aogi, K., Minami, H., et al. (2005) Zoledronic Acid Significantly Reduces Skeletal Complications Compared with Placebo in Japanese Women with Bone Metastases from Breast Cancer: A Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology, 23, 14-21.
https://doi.org/10.1200/JCO.2005.05.116

[7] Early Breast Cancer Trialists’ Collaborative Group, Coleman, R., Powles, T., Paterson, A., et al. (2015) Adjuvant Bisphosphonate Treatment in Early Breast Cancer: Meta-Analyses of Individual Patient Data from Randomised Trials. Lancet, 386, 1353-1361.
https://doi.org/10.1016/S0140-6736(15)60908-4

[8] Liede, A., Jerzak, K.J., Hernandez, R.K., et al. (2016) The Incidence of Bone Metastasis after Early-Stage Breast Cancer in Canada. Breast Cancer Research and Treatment, 156, 587-595.
https://doi.org/10.1007/s10549-016-3782-3

[9] Irawan, C., Atmakusumah, D., Siregar, N.C., et al. (2016) Expression of Biomarkers CXCR4, IL11-RA, TFF1, MLF1P in Advanced Breast Cancer Patients with Bone Metastatic: a Diagnostic Study. Acta Medica Indonesiana, 48, 261-268.

[10] Chiu, J.H., Wen, C.S., Wang, J.Y., et al. (2017) Role of Estrogen Receptors and Src Signaling in Mechanisms of Bone Metastasis by Estrogen Receptor Positive Breast Cancers. Journal of Translational Medicine, 15, 97.
https://doi.org/10.1186/s12967-017-1192-x

[11] Koizumi, M., Yoshimoto, M., Kasumi, F., et al. (2003) Comparison between Solitary and Multiple Skeletal Metastatic Lesions of Breast Cancer Patients. Annals of Oncology, 14, 1234-1240.
https://doi.org/10.1093/annonc/mdg348

[12] Lee, S.J., Park, S., Ahn, H.K., et al. (2011) Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer. Cancer Research and Treatment, 43, 89-95.
https://doi.org/10.4143/crt.2011.43.2.89

[13] Sciubba, D.M., Gokaslan, Z.L., Suk, I., et al. (2007) Positive and Negative Prognostic Variables for Patients Undergoing Spine Surgery for Metastatic Breast Disease. European Spine Journal, 16, 1659-1667.
https://doi.org/10.1007/s00586-007-0380-4